Tag
Neoadjuvant therapy alters key prognostic factors in resected pancreatic ductal adenocarcinoma, enabling personalized survival prediction models distinct from chemo-naïve patients.
This study reveals that CLDN18.2 acquired by CD8+ T cells through trogocytosis impairs their glucose metabolism and cytotoxic function, promoting pancreatic cancer progression and systemic immune senescence. Targeting this axis may enhance
This study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-te
A propensity-matched study shows adding radiotherapy to neoadjuvant chemotherapy improves pathologic response but does not enhance survival or reduce recurrence in resected pancreatic ductal adenocarcinoma.
NSUN6 deficiency in pancreatic cancer promotes immune suppression by enhancing immunosuppressive macrophage infiltration via the KDM5A-CCL2 axis, leading to resistance to immune checkpoint blockade; targeting this pathway offers a promising
This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.
A multi-institutional AI model identified pre-diagnostic pancreatic cancer on routine CT with meaningful lead time, higher sensitivity than radiologists, longitudinal stability, and externally validated specificity in a low-prevalence setti
